Deo logo
 
You are here: Division of Experimental Oncology > Group Rufer

Group Nathalie Rufer

Cancer therapy with cytolytic T lymphocytes

ruferstrip.jpg

T lymphocytes are specialized mediators of adaptive immunity that circulate in the body. They recognize and destroy any diseased cells which have been altered, e.g. by infection with a virus or by transformation into cancer cells. Although tumor-specific cytolytic T cells can be detected in patients suffering from cancer, these immune responses often fail to control or eliminate the disease. Therapeutic vaccines aim at inducing and boosting specific T cells mediated immunity to reduce tumor burden. Such approaches provide a unique opportunity to study T-cell priming and memory formation in humans. All projects described thereafter are aimed to improve the possibilities for using tumor-specific cytolytic T lymphocytes in anti-cancer therapy.

 


Search:
 in this site:
   
   
 Rechercher

Chemin des Boveresses 155 - CH-1066 Epalinges  - Switzerland  -  Phone +41 21 692 58 42  -  Fax  +41 21 652 69 33